Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

1.

Tumor Microenvironmental Changes Induced by the Sulfamate Carbonic Anhydrase IX Inhibitor S4 in a Laryngeal Tumor Model.

Meijer TW, Bussink J, Zatovicova M, Span PN, Lok J, Supuran CT, Kaanders JH.

PLoS One. 2014 Sep 16;9(9):e108068. doi: 10.1371/journal.pone.0108068. eCollection 2014.

PMID:
25225880
[PubMed - in process]
Free Article
2.

Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma.

Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der Heijden EH, Oyen WJ, Visser EP, Span PN, Bussink J.

J Thorac Oncol. 2014 Aug 28. [Epub ahead of print]

PMID:
25170642
[PubMed - as supplied by publisher]
3.

The unfolded protein response as a target for cancer therapy.

Nagelkerke A, Bussink J, Sweep FC, Span PN.

Biochim Biophys Acta. 2014 Jul 25;1846(2):277-284. doi: 10.1016/j.bbcan.2014.07.006. [Epub ahead of print] Review.

PMID:
25069067
[PubMed - as supplied by publisher]
4.

Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy.

Nagelkerke A, Bussink J, Geurts-Moespot A, Sweep FC, Span PN.

Semin Cancer Biol. 2014 Jun 14. pii: S1044-579X(14)00076-5. doi: 10.1016/j.semcancer.2014.06.001. [Epub ahead of print] Review.

PMID:
24933034
[PubMed - as supplied by publisher]
5.

Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Cavalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P.

Nat Commun. 2014 Jun 3;5:4006. doi: 10.1038/ncomms5006.

PMID:
24892406
[PubMed - in process]
Free PMC Article
6.

Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy.

Nagelkerke A, Sweep FC, Geurts-Moespot A, Bussink J, Span PN.

Semin Cancer Biol. 2014 May 29. pii: S1044-579X(14)00073-X. doi: 10.1016/j.semcancer.2014.05.004. [Epub ahead of print] Review.

PMID:
24879905
[PubMed - as supplied by publisher]
7.

Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinoma.

van de Schootbrugge C, Schults EM, Bussink J, Span PN, Grénman R, Pruijn GJ, Kaanders JH, Boelens WC.

BMC Cancer. 2014 Apr 11;14:252. doi: 10.1186/1471-2407-14-252.

PMID:
24725344
[PubMed - in process]
Free PMC Article
8.

Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.

Heijmen L, Ter Voert EG, Punt CJ, Heerschap A, Oyen WJ, Bussink J, Sweep CG, Laverman P, Span PN, de Geus-Oei LF, Boerman OC, van Laarhoven HW.

Contrast Media Mol Imaging. 2014 May-Jun;9(3):237-45. doi: 10.1002/cmmi.1564.

PMID:
24700751
[PubMed - in process]
9.

Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors.

Stegeman H, Rademakers SE, Span PN, Takes RP, van der Kogel AJ, Kaanders JH, Bussink J.

Head Neck. 2014 Sep;36(9):1288-95. doi: 10.1002/hed.23446. Epub 2013 Nov 6.

PMID:
24668936
[PubMed - in process]
10.

Hypoxic regulation of the PERK/ATF4/LAMP3-arm of the unfolded protein response in head and neck squamous cell carcinoma.

Nagelkerke A, Sweep FC, Stegeman H, Grénman R, Kaanders JH, Bussink J, Span PN.

Head Neck. 2014 Mar 14. doi: 10.1002/hed.23693. [Epub ahead of print]

PMID:
24634103
[PubMed - as supplied by publisher]
11.

Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors.

Hoeben BA, Starmans MH, Leijenaar RT, Dubois LJ, van der Kogel AJ, Kaanders JH, Boutros PC, Lambin P, Bussink J.

BMC Cancer. 2014 Feb 26;14:130. doi: 10.1186/1471-2407-14-130.

PMID:
24571588
[PubMed - in process]
Free PMC Article
12.

18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.

Hoeben BA, Troost EG, Bussink J, van Herpen CM, Oyen WJ, Kaanders JH.

Nuklearmedizin. 2014;53(2):60-6. doi: 10.3413/Nukmed-0625-13-09. Epub 2014 Jan 28.

PMID:
24468965
[PubMed - in process]
13.

Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.

Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Takes RP, de Bree R, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH.

Clin Cancer Res. 2014 Mar 1;20(5):1345-54. doi: 10.1158/1078-0432.CCR-13-1730. Epub 2014 Jan 22.

PMID:
24452791
[PubMed - in process]
14.

LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.

Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN.

Endocr Relat Cancer. 2014 Jan 16;21(1):101-12. doi: 10.1530/ERC-13-0183. Print 2014 Feb.

PMID:
24434718
[PubMed - indexed for MEDLINE]
15.

Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, Boerman OC.

J Nucl Med. 2014 Feb;55(2):281-6. doi: 10.2967/jnumed.113.129668. Epub 2014 Jan 9.

PMID:
24408894
[PubMed - indexed for MEDLINE]
16.

Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial.

Rademakers SE, Hoogsteen IJ, Rijken PF, Terhaard CH, Doornaert PA, Langendijk JA, van den Ende P, van der Kogel AJ, Bussink J, Kaanders JH.

Head Neck. 2013 Dec 17. doi: 10.1002/hed.23569. [Epub ahead of print]

PMID:
24347430
[PubMed - as supplied by publisher]
17.

Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.

Arens AI, Troost EG, Hoeben BA, Grootjans W, Lee JA, Grégoire V, Hatt M, Visvikis D, Bussink J, Oyen WJ, Kaanders JH, Visser EP.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):915-24. doi: 10.1007/s00259-013-2651-0. Epub 2013 Dec 18.

PMID:
24346414
[PubMed - in process]
18.

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.

Stegeman H, Kaanders JH, Verheijen MM, Peeters WJ, Wheeler DL, Iida M, Grénman R, van der Kogel AJ, Span PN, Bussink J.

Mol Cancer. 2013 Nov 5;12(1):133. doi: 10.1186/1476-4598-12-133.

PMID:
24192080
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.

van Dijk LK, Hoeben BA, Kaanders JH, Franssen GM, Boerman OC, Bussink J.

J Nucl Med. 2013 Dec;54(12):2118-24. doi: 10.2967/jnumed.113.123612. Epub 2013 Oct 17.

PMID:
24136932
[PubMed - indexed for MEDLINE]
20.

EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair.

Stegeman H, Span PN, Cockx SC, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH, Bussink J.

Radiat Res. 2013 Oct;180(4):414-21. doi: 10.1667/RR3349.2. Epub 2013 Sep 23.

PMID:
24059677
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk